ArticleScientific reports2025
Exploring the molecular interaction of bioactive peptides with antioxidative, antidiabetic and anti-inflammatory attributes from sheep milk fermented with lactobacillus and yeast.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Microbial Fermentation as a Tool to Improve the Antioxidant and Functional Value of Milk Products.Foods (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sheep milk is a rich source of proteins with potential to generate bioactive peptides through microbial fermentation. However, limited studies have focused on the Panchali sheep breed of India and the multifunctional health properties of its fermented products. This study investigated the generation of bioactive peptides with antidiabetic, antioxidative, and anti-inflammatory properties through the fermentation of sheep milk using a potent LAB, Limosilactobacillus fermentum (KGL4, MTCC 25515), in combination with the yeast strain Saccharomyces cerevisiae (WBS2A, MG101828). Optimal bioactivity was observed after 48 h of fermentation at 30 °C, with antioxidant activity reaching 40.08%, α-amylase inhibition at 72.48%, and α-glucosidase inhibition at 75.96%. Proteolytic activity was assessed at varying inoculum concentrations (1.5, 2 and 2.5%) and incubation time (0, 12, 24, 36 and 48 h), with the highest activity (6.74 mg/mL) observed at a 2.5% inoculum after 48 h. Additionally, fermented milk effectively lowered the production of pro-inflammatory cytotoxins and ROS in LPS-induced RAW 267.4 macrophage cells, indicating its anti-inflammatory properties. Protein profiling through SDS-PAGE revealed bands between 15 and 70 kDa, while 2D electrophoresis identified 39 distinct protein spots associated with peptide production. Reverse-phase HPLC of ultrafiltered water-soluble extracts (WSEs) was used to separate peptide fractions, and identified sequences were assessed through comparison with BIOPEP database to confirm antidiabetic and antioxidative activities. The most potent selected peptide showed strong binding affinity and stable interaction within the active pockets of human α-amylase and α-glucosidase, as well as high HADDOCK and HPEPDOCK scores in molecular docking analyses. These findings indicate that fermented sheep milk is a promising source of multifunctional bioactive peptides with potential applications in functional foods targeting diabetes and inflammation. Further in vivo studies are warranted to validate physiological relevance, bioavailability, and health benefits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.